Helicobacter pylori: Rational management options

American Journal of Medicine

Volumn 105, Issue 5, 1998, Pages 424-430

  Peura, David ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH SALICYLATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HELICOBACTER PYLORI; HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW;

DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 0032212505     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00297-6     Document Type: Review

References (43)

1. 1. DeCross AJ, Marshall BJ. The role of Helicobacter pylori in acid-peptic disease. Am J Med Sci. 1993;306:381-392.
2. 2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65-69.
3. 3. Hunt RH. Eradication of Helicobacter pylori infection. Am J Med. 1996;100(suppl 5A):42S-51S.
4. 4. Tytgat GNJ, Noach LA, Rauws EAJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin North Am. 1993;22: 127-139.
5. 5. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med. 1992;116:705-708.
6. 6. Tytgat GNJ. Long-term consequences of Helicobacter pylori eradication. Scand J Gastroenterol. 1994;29(suppl 205):38-44.
7. 7. Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994;343:258-260.
8. 8. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. NEJM. 1993;328:349-350.
9. 9. Peura D. The report of the Digestive Health Initiative International Update Conference in Helicobacter pylori. Gastroenterol. 1997; 113: S4-S8.
10. 10. Fendrick AM, Hirth RA, Chernew ME. Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. Am J Gastroenterol. 1996;91:1544-1548.
11. 11. Roll J, Weng A, Newman J. Diagnosis and treatment of Helicobacter pylori infection among California Medicare patients. Arch Intern Med. 1997;157:994-998.
12. 12. Vakil N, Mc Call T. Changes in primary care approaches to H pylori diagnosis and treatment in 1996. Gastroenterology. 1997;112:A318.
13. 13. Rauws EAJ. Role of Helicobacter pylori in duodenal ulcer. Drugs. 1992;44:921-927.
14. 14. Vakil N, Fennerty MB. The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Am J Med. 1996; 100(suppl 5A):60S-64S.
15. 15. Cutler AF. Testing for Helicobacter pylori in clinical practice. Am J Med. 1996;100(suppl 5A):35S-41S.
16. 16. Guay DRP, Gilberstadt SJ. Antimicrobial management of Helicobacter pylori-associated gastrointestinal tract disease. Arch Fam Med. 1997;6;173-180.
17. 17. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol. 1997; 43:223-243.
18. 18. Damianos AJ, McGarrity TJ. Treatment strategies for Helicobacter pylori infection. Am Fam Phys. 1997;55:2765-2774.
19. 19. Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med. 1997;157:87-97.
20. 20. Graham DY, de Boer WA, Tytgat GN. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol. 1996;91:1072-1076.
21. 21. Fennerty B. Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. Am J Gastroenterol. 1998;93:2-3.
22. 22. 1997 Redbook Update. Montvale, NJ: Medical Economics. October 1997.
23. 23. Levin TR, Schmittdiel JA, Henning JM, et al. A cost analysis of a Helicobacter pylori eradication strategy in a large Health Maintenance Organization. Gastroenterology. 1997;112:A25.
24. 24. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996;91:239-245.
25. 25. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. Ann Intern Med. 1991;115:266-269.
26. 26. Cutler AF, Schubert TT. Long-term Helicobacter pylori recurrence after successful eradication with triple therapy. Am J Gastroenterol. 1993;88:1359-1361.
27. 27. Axon ATR. The potential value of lansoprazole in Helicobacter pylori eradication. J Clin Gastroenterol. 1995;20(suppl 1):S43-S47.
28. 28. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102:493-496.
29. 29. Peterson W, Ciociola A, Sykes D, et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H pylori and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10:251-261.
30. 30. Lanza F, Ciociola A, Sykes D, et al. Ranitidine bismuth citrate plus clarithromycin is effective in eradicating H pylori, healing duodenal ulcers, and preventing ulcer relapse. Gastroenterology. 1996;110:A172.
31. 31. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. NEJM. 1995;333: 984-991.
32. 32. Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994;48:404-430.
33. 33. Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1994;48: 91-132.
34. 34. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol. 1994;29(suppl 201): 16-23.
35. 35. Markham A, McTavish D. Clarithromycin and omeprazole as H pylori eradication therapy in patients with H pylori-associated gastric disorders. Drugs. 1996;51:161-178.
36. 36. O'Morian C, Dettmer A, Rambow A, et al. Double-blind, multicenter placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. Helicobacter. 1996;1:130-137.
37. 37. Harford W, Lanza F, Arora A, et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter. 1996;1:243-250.
38. 38. Schwartz H, Krause R, Sahba B, et al. Triple vs dual therapy with lansoprazole, clarithromycin and or amoxicillin in the eradication of Helicobacter pylori. Am J Gastroenterol. 1996;91:A641.
39. 39. Langtry H, Wilde. Lansoprazole: update in acid-related disorders. Drugs. 1997;54:473-500.
40. 40. Fennerty B, Bianchi T, Rose P, et al. Triple therapy with lansoprazole, clarithromycin, and amoxicillin in the eradication of Helicobacter pylori infection. Gastroenterology. 1997;112:A116.
41. 41. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology. 1997;113:S131-S148.
42. 42. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter. 1996;1:138-144.
43. 43. Mégraud F, Lehn N, Lind T, et al. The MACH 2 study. Helicobacter pylori resistance to antimicrobial agents and its influence on clinical outcome. Gastroenterology. 1997;112:A216. Abstract.